Unity Biotechnology, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $236,000 | $4.8M | $0 | $0 |
| Operating income | −$31.2M | −$44.7M | −$57.6M | −$56.7M | −$93.9M | −$89.7M |
| Net income | −$26.0M | −$39.9M | −$44.5M | −$60.7M | −$93.8M | −$82.2M |
| Total assets | $37.7M | $65.7M | $136.2M | $124.7M | $156.3M | $151.2M |
| Total liabilities | $31.2M | $37.3M | $75.2M | $65.1M | $73.4M | $30.5M |
| Equity | $6.5M | $28.4M | $56.1M | $59.6M | $82.9M | $120.7M |
| EPS (diluted) | $-1.54 | $-2.70 | $-4.68 | $-10.88 | $-18.45 | — |
| Shares out. | 16.8M | 14.3M | 68.9M | 54.7M | 47.6M | 42.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −400.2%
- Return on assets
- −69.0%
- Return on capital (ROCE)
- −109.7%
- Liabilities / assets
- 82.8%
- Debt / equity
- 4.80×
- Book value / share
- $0.39
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -46.90distress
- Accruals / assets
- −13.6%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 2, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Arch Venture Fund Vii, L.P.Passive (13G)Nov 14, 2025
- Alyeska Investment Group, L.P.Passive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Nguyen Alexander HieuOfficer — CLO and Head of Ops | Apr 2, 2025 | Sell | 17,852 | $1.03 |
| Sullivan Lynne MarieOfficer — CFO & Head of Corp. Dev. | Apr 2, 2025 | Sell | 21,867 | $1.03 |
| Ghosh AnirvanOfficer — Chief Executive Officer | Apr 2, 2025 | Sell | 96,797 | $1.03 |
| Nguyen Alexander HieuOfficer — CLO and Head of Ops | Mar 27, 2025 | Sell | 1,954 | $1.16 |
| Sullivan Lynne MarieOfficer — CFO & Head of Corp. Dev. | Mar 28, 2025 | Grant | 65,000 | $0.00 |
| Ghosh AnirvanOfficer — Chief Executive Officer | Mar 28, 2025 | Grant | 175,000 | $0.00 |
| Sullivan Lynne MarieOfficer — CFO & Head of Corp. Dev. | Feb 4, 2025 | Sell | 153 | $2.23 |
| Nguyen Alexander HieuOfficer — CLO and Head of Ops | Feb 4, 2025 | Sell | 164 | $2.23 |
| Ghosh AnirvanOfficer — Chief Executive Officer | Feb 4, 2025 | Sell | 642 | $2.23 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Modified shareholder rightsSep 26, 2025
- Shareholder voteSep 19, 2025
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Amended charter or bylawsJul 22, 2025
- Delisting / listing-standard notice · Director / officer change · Other material eventJun 30, 2025
- Delisting / listing-standard noticeJun 20, 2025
- Costs from exit or disposal · Director / officer change · Other material eventMay 5, 2025
- Results of operationsApr 22, 2025
- Director / officer changeApr 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.